| Literature DB >> 35326946 |
Seongmin Kim1, Hwajung Lee2, Sanghoon Lee2, Jae-Yun Song2, Jae-Kwan Lee2, Nak-Woo Lee2.
Abstract
The accuracy of colposcopic diagnosis depends on the skill and proficiency of physicians. This study evaluated the feasibility of interpreting colposcopic images with the assistance of artificial intelligence (AI) for the diagnosis of high-grade cervical intraepithelial lesions. This study included female patients who underwent colposcopy-guided biopsy in 2020 at two institutions in the Republic of Korea. Two experienced colposcopists reviewed all images separately. The Cerviray AI® system (AIDOT, Seoul, Korea) was used to interpret the cervical images. AI demonstrated improved sensitivity with comparable specificity and positive predictive value when compared with the colposcopic impressions of each clinician. The areas under the curve were greater with combined impressions (both AI and that of the two colposcopists) of high-grade lesions, when compared with the individual impressions of each colposcopist. This study highlights the feasibility of the application of an AI system in cervical cancer screening. AI interpretation can be utilized as an assisting tool in combination with human colposcopic evaluation of exocervix.Entities:
Keywords: artificial intelligence; cervical cancer screening; colposcopy; deep learning; machine learning
Year: 2022 PMID: 35326946 PMCID: PMC8953422 DOI: 10.3390/healthcare10030468
Source DB: PubMed Journal: Healthcare (Basel) ISSN: 2227-9032
Figure 1A diagram of Cerviray AI® interpretation for colposcopic images. The system assesses the visibility of the images, and recognizes the squamocolumnar junction and transformation zone of the uterine cervix. If the image is satisfactory for evaluation, the image is processed and normalized for AI feature extraction. This is followed by the classification of images according to the AI impression.
Clinical Characteristics of Study Population.
| Characteristics | Value |
|---|---|
| Age, years | 36.9 ± 8.9 |
| Cytological results | |
| Normal | 5 (2.1) |
| ASC-US | 107 (45.7) |
| LSIL | 67 (28.6) |
| ASC-H/HSIL | 52 (22.2) |
| SCC | 3 (1.3) |
| HPV status | |
| Positive for high-risk | 153 (65.4) |
| Positive for low-risk only or negative | 16 (6.8) |
| Not done | 65 (27.8) |
| Histopathology | |
| Benign | 52 (22.2) |
| CIN1 | 66 (28.2) |
| CIN2-3 | 110 (47.0) |
| Invasive cancer | 6 (2.6) |
| Treatment | |
| Observation and follow-up | 111 (47.4) |
| LEEP/Conization | 107 (45.7) |
| Extrafascial hysterectomy | 5 (2.1) |
| Radical hysterectomy | 4 (1.7) |
| Chemotherapy/Radiotherapy | 2 (0.9) |
| Refusal of treatment | 5 (2.1) |
Values are expressed as mean ± standard deviation or number (%). ASC-H: atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesions; ASC-US, atypical squamous cells of unknown significance; CIN, cervical intraepithelial neoplasia; HSIL, high-grade squamous intraepithelial lesion; HPV, human papilloma virus; LEEP, loop electrosurgical excision procedure; LSIL, low-grade squamous intraepithelial lesion.
Distribution of the colposcopic findings, AI interpretations, and histopathology according to the cytology results.
| Cytology | Impression | Doctor 1 | Doctor 2 | AI | Histopathology |
|---|---|---|---|---|---|
| Normal | Non-specific/Benign | 2 | 2 | 3 | 4 |
| Minor/CIN1 | 2 | 3 | 2 | 0 | |
| Major/CIN2-3 | 1 | 0 | 0 | 1 | |
| ASC-US | Non-specific/Benign | 28 | 35 | 43 | 37 |
| Minor/CIN1 | 50 | 32 | 30 | 34 | |
| Major/CIN2-3 | 32 | 39 | 32 | 35 | |
| Suspicious for invasion/Cancer | 0 | 1 | 2 | 1 | |
| LSIL | Non-specific/Benign | 15 | 14 | 20 | 7 |
| Minor/CIN1 | 37 | 32 | 24 | 29 | |
| Major/CIN2-3 | 15 | 21 | 22 | 31 | |
| Suspicious for invasion/Cancer | 0 | 0 | 1 | 0 | |
| ASC-H/ | Non-specific/Benign | 4 | 4 | 7 | 4 |
| Minor/CIN1 | 6 | 9 | 5 | 3 | |
| Major/CIN2-3 | 41 | 38 | 37 | 43 | |
| Suspicious for invasion/Cancer | 1 | 1 | 3 | 2 | |
| SCC | Suspicious for invasion/Cancer | 3 | 3 | 3 | 3 |
Values are expressed as a number. AI, artificial intelligence; ASC-H, atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesions; ASC-US, atypical squamous cells of unknown significance; CIN, cervical intraepithelial neoplasia; HSIL, high-grade squamous intraepithelial lesion; LSIL, low-grade squamous intraepithelial lesion; SCC, squamous cell carcinoma.
Evaluation of the diagnostic quality of various tools in detecting high-grade or worse lesions versus less severe impressions.
| Method | Sensitivity | Specificity | PPV |
|---|---|---|---|
| Cytology | 41.38 | 94.07 | 87.27 |
| Doctor 1 | 71.55 | 87.29 | 84.69 |
| Doctor 2 | 69.83 | 81.36 | 78.64 |
| AI interpretation | 74.14 | 83.05 | 81.13 |
| Doctor 1 + AI | 84.48 | 77.97 | 79.03 |
| Doctor 2 + AI | 83.62 | 74.58 | 76.38 |
AI, artificial intelligence; PPV, positive predictive value; Doctor 1 + AI, if Doctor 1 accepted the more aggressive impressions of AI despite disagreements; Doctor 2 + AI, if Doctor 2 accepted the more aggressive impressions of AI despite disagreements.
Figure 2ROC curves of each diagnostic performance for detecting high-grade or worse lesion versus less severe impressions. (a) AI interpretation; (b) colposcopic impression of Dr 1; (c) colposcopic impression of Dr 2; (d) combined impression of AI and Dr1 colposcopy; (e) combined impression of AI and Dr2 colposcopy; (f) cytology.
Figure 3Correlations between each diagnostic tool. Values are expressed as Pearson’s R (p-value).
Figure 4An algorithm of the deep learning process of Cerviray AI®. Briefly, it included the input of an image, multiple convolution and deconvolution networks of image processing while pooling and dropping out of data, and output of the result.